Krishna Institute of Medical Sciences | BUY

Thane asset breaks ground

We visited the newly commisioned Thane KIMS hospital and met the CFO, Mr. Sachin Salvi. The KTAs from the meeting are as follows:

- Asset operationalization: KIMS Thane Hospital, located in the Hiranandani Complex on Ghodbunder Road, commenced operations on May 1, 2025. The Outpatient Department (OPD) began functioning on May 1, while Inpatient Department (IPD) services started on May 19. As of now, 100 ward beds and 3 OTs are operational. Current occupancy levels are approximately 40% for ward beds and 80% for OTs.
- Asset details: It is a 300-bed multispecialty hospital spread across six floors, comprising approximately 220 ward beds, around 40 ICU beds, and 10 operation theatres (OTs). The 6th floor houses presidential and luxury suites, priced at discounted rates ranging from INR 25,000 to INR 35,000 per day.
- Manpower allocation: Most inpatient departments have started operations, except for Cardiac and Oncology services. A total of 85–90 doctors are expected to be onboarded in the first phase, with over 60 doctors already joined. Additional consultants are scheduled to join in July–August. Many of the doctors have been hired from reputed institutions such as Jaslok, Fortis, and Jupiter hospitals.
- Demand analysis: The surrounding locality includes premium residential developments by Lodha, Hiranandani, and Kalpataru, with the Hiranandani Complex alone expected to have a population of approximately 100,000. Given the ongoing real estate development in the area, optimal occupancy is expected to be reached quickly once the hospital is fully operational.
- Financials: By March 2026, the hospital aims to reach a monthly exit run rate of INR 200–250mn in our view. The ramp-up has been significantly faster than initially anticipated, and the hospital is likely to achieve break-even within its first year of operations.
- Our view: KIMS remains one of the top picks in hospital space due to growing presence in Metro cities which will help in expanding brand as well as operational matrix and attractive valuations vs peers.

Amey Chalke amey.chalke@jmfl.com | Tel: (91 22) 66303056

JM Financial Research is also available on: Bloomberg - JMFR <GO>, Thomson Publisher & Reuters, S&P Capital IQ, FactSet and Visible Alpha

Please see Appendix I at the end of this report for Important Disclosures and Disclaimers and Research Analyst Certification.






Source: Company, JM Financial

Dr. Valkaal Velez Dr. Kalada Dranspace Dr. Kalada Dranspace Dr. Kalada Dranspace MAALSTERECOV Electronic Strangene Dr. Kalada Dranspace Dr. Kalada Dranspace Dr. Manka Agassani Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Manka Agassani Dr. Karler Marka Dr. Manka Agassani Dr. Karler Marka Dr. Marka Magassani Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr. Karler Marka Dr.					hyt-
Dr. Ankit Synei		DOCT	OR DIRE	CTORY	
IP: Marchart Nutzer Dr. Kanakart Daugagada Dr. Kanakart Dau	New Source and a state of the second s	DIABETOLOGY	NEURO SURGERY	RADIATION ONCOLOGY	RHEUMATOLOGY
ANLESTIGEOLOGY Dir Rang begin U. K.R.D. Hank Agamma Dir Rang begin Dir Rang begin Dir Rang begin Dir. Missin Agamma Dir Sunit Mission Dir Konstansk Mission Dir Konstansk Mission Dir Rang begin Dir. Missin Agamma Dir Sunit Mission Dir Konstansk Mission	Dr. Ankit Biyani	Dr. Vijay Negalur	Dr. Ujwal Yeole	Dr. Sagar Gayakwad	Dr. Natasha Negalur
Dr. Reten Agazene Dr. Stant Burg Dr. Reten Agazene RCELA USCOCH Dr. Reten Agazene Dr. Stant Reten Dr. Reten Agazene Dr. Stant Rete	Dr. Valshali Yadav	Dr. Manish Deshpande	Dr. Kapil Khandelwal	PULMONOLOGY	Dr. Ruby Taparia
Br. Physicals Burde UT Dr. Bould Burde Dr. Bould Burde <td>ANAESTHESIOLOGY</td> <td>ENDOCRINOLOGY</td> <td>Dr. Naron Nayak</td> <td>Dr. Ravindra Sangiikar</td> <td>SURG GASTROENTEROLO</td>	ANAESTHESIOLOGY	ENDOCRINOLOGY	Dr. Naron Nayak	Dr. Ravindra Sangiikar	SURG GASTROENTEROLO
Brit Smull Singhal Dir. Angel Areas Dir. Smull Singhal Dir. Angel Areas Dir. Manus Minglar Dir. Manus	Dr. Nitesh Agawane	Dr. Sukirti Misra	Dr. Hrushikesh Kharosekhar	Dr. Ravindra Rupwate	Dr. Sachin Wani
B. Manish Rovel (Cashic) ESSIAd Structure Dir. Karlag Statistic Dir. Structure	Dr. Priyanka Burde	ENT	Dr. Deepu Banerji	Dr. Jaspreet Singh Khandpur	Dr. Hemant Jain
Dr. Lenns Reynheit Dr. Rugel Spreich Turke Dr. Rugel Spreich Turke <thdr. rugel="" spreich="" td="" tu<=""><td>Dr. Shruti Singhal</td><td>Dr. Archana S</td><td>DESTETRICS & GYNAECOLOGY</td><td>Dr. Manas Mengar</td><td>MED GASTROENTEROLOGY</td></thdr.>	Dr. Shruti Singhal	Dr. Archana S	DESTETRICS & GYNAECOLOGY	Dr. Manas Mengar	MED GASTROENTEROLOGY
Die Ausschaften Die Steinder Steinder Jereih Die Ausschaften Die Ausschaften Die Burg Berland Die Ausschaften Die Ausschaften Die Ausschaften Die Ausschaften Die Kunst Berland Die Ausschaften Die Ausschaften Die Ausschaften Die Ausschaften Die Ausschaften Die Kunst Berland Die Ausschaften D	Dr. Mandar Deval (Cardiac	FOETAL MEDICINE	Dr. Vidya Shetty	PEDIATRICS	Dr. Manish Dodmani
Dr. Brick, Galaxies Dr. Avisteen Nation Dr. Bricken Nation Dr. B	Dr. Leena Tayshete	Dr. Rupal Parekh Tulle	Dr. Sujata Rathod	Dr. Sudam Mungai	SPINE SURGERY
Ber C. Janssen Ber C. Janssen B	CARDIOLOGY	GENERAL SURGERY	Dr. Shailendra Jadhav	PEDIATRIC CRITICAL CARE	Dr. Amogh Zawar
Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Syman Raman Dr. Sy	Dr. B. C. Kalmath	Dr. Arulvanan Nandan	Dr. Shruti Chandak	Dr. Guruprasad Shanbhag	Dr. Jøyesh Bhanushali
Dr. Augerikanskimi Dr. Samole Result Dr. Samole Result Dr. Augerikanskimi Dr. Augerikanskimi Dr. Kangel Passimi Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Augerikanskimi Dr. Kangel Passimi Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Augerikanskimi Dr. Kangel Passimi Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Augerikanskimi Dr. Kangel Passimi Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Kangel Passimi Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Manifer Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Manifer Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Manifer Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Manifer Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Manifer Result Dr. Samole Result Dr. Samole Result Dr. Samole Result Dr. Samole Result </td <td>Dr. Varun Bhotia</td> <td>Dr. Jully Bhagvat</td> <td>Dr. Rokha Thote</td> <td>Dr. Jaykishan Tripathi</td> <td>UROLOGY</td>	Dr. Varun Bhotia	Dr. Jully Bhagvat	Dr. Rokha Thote	Dr. Jaykishan Tripathi	UROLOGY
Dr. Analy Takakoli MPKChOld Stability Dr. Analy Takakoli MPKChOld Stability Dr. Analy Terrent, MPKChOR Dr. Sanda Charanton Dr. Marking Stam MPKChORD Stability Dr. Sandy Stability MPKChORD Stability Dr. Sandy Stability MPKChORD Stability Dr. Sandy Charanton Dr. Sandy Charanton Dr. Sandy Stability MPKChORD Stability Dr. Sandy Stability Dr. Sandy Stability Dr. Sandy Stab	Dr. Dayanand Kumbla	Dr. Samper Rege	Dr. Jayant Chaudhari	PEDIATRIC CARDIOLOGY	Dr. Sandesh Parab
Dr. Krawie (Hill) Dr. Angel Hall Dr.	Dr. Anup Taksando	INFECTIOUS DISEASES	OPHTHALMOLOGY	Dr. Srinivas L	Dr. Aakil Khan
Dr. Namion Shortway METERIAL MERCORE (NAMION Shortway) METERIAL M	Dr. Pankai Patil	Dr. Prosti Pillai	Dr. Chaitanya Vemu	Dr. Sonia Karapurkar	Dr. Ajit Gujela
CY12 D. Ankiel Muri Critovococo D. Sund S. S. Dr. Sund Sanamani D. Sund S. S. D. Sund S. S. D. Sund S. S. Dr. Sund Cabin D. Sund X. S. D. Sund X. S. D. Sund X. S. Dr. Sund Cabin D. Sund X. Sunamania D. Sund X. Sunamania D. Sund X. Sunamania Dr. Sund Cabin D. Sund X. Sunamania D. Sund X. Sunamania D. Sunama X. Sunamania Dr. Sund Cabin M. Sunama X. Sunamania D. Sunama X. Sunamania D. Sunama X. Sunamania Critical Sunama D. Sunama X. Sunamania D. Sunama X. Sunamania D. Sunama X. Sunamania Dr. Sunama X. Sunamania D. Sunama X. Sunamania D. Sunama X. Sunamania D. Sunama X. Sunamania Dr. Sunama X. Sunamania D. Sunama X. Sunamania D. Sunama X. Sunamania D. Sunama X. Sunamania D. Sunama X. Sunamania Dr. Sunama X. Sunama D. Sunama X. Sunamania D. Sunama X. Sunamania D. Sunama X. Sunamania D. Sunama X. Sunamania Dr. Sunama X. Sunama X. Sunamania D. Sunama X. Sunamania D. Sunama X. Sunamania D. Sunama X. Sunamania D. Sunama X. Sunamania Dr. Sunama X. Sunamani Dr. Sunama X. Sunamania		INTERNAL MEDICINE	Dr. Rashmi Barve	PEDIATRIC CARDIAC SURGERY	VASCULAR SURGERY
Dr. Samys B., Jensammett Dr., Stellan Goglat Dr., Perkh Agranut PEDLATER, Stellar VI Dr. Anard Gambel Dr. Bender Krahmet Dr. Samys Datagenet Dr., Bender Krahmet Dr. Samys Datagenet Dr., Bender Krahmet Dr. Samys Datagenet Dr., Bender Krahmet Dr., Kanne Kannel Dr., Bend Bannet Dr., Kanne Kannel Dr., Kannel Kannel	Representation of the second second	Dr. Anikat Mule	ORTHOPEDICS	Dr. Sunil G. S	
Dr. Annord Galank Dr. Sturder Kreinham Dr. Sturder Kreinha		Dr. Shilpa Gupta	Dr. Parth Agrawal	PEDIATRIC SURGERY	and a second of the second sec
Dr. Samper Johns MICRAMINAL MADEGORY Dr. Samp Developed MICROFTAUL CALL DV. Samp Developed Dr. March March DO. Dr. March March DO. Dr. March March DO. DY. Samp Developed Dr. March Manch DO. Dr. March March DO. Dr. March March DO. DY. Samp Developed Dr. March Manch DO. Dr. March March DO. Dr. March March DO. DY. Samp Developed Dr. March Manch DO. Dr. March March DO. Dr. March March DO. DY. Samp Developed Dr. March March DO. Dr. March March MO. Dr. March March MO. DY. Samp Developed Restored March MO. Dr. March March MO. Dr. March March MO. DY. Samp Developed Dr. March March MO. Dr. March March MO. Dr. March March MO. DY. Samp Developed Dr. March March March MO. Dr. March March MARCH MO. Dr. March March MARCH MO. DY. Samp Developed Dr. March March March MARCH MO. Dr. March March MARCH MO. Dr. March March MARCH MO. Dr. March March March MARCH MO. DY. Samp Developed M. Dr. Samp Developed M. Dr. Samp March March MARCH MO. Dr. March March MARCH MO. Dr. Verse Doil Dr. Samp March March March MARCH MO. Dr. Ma	Contraction of the owner of the owner of the		Dr. Swapnil Zambora	Dr. Jeovan Gereil	
Dr. Monia Prakati Dr. Mania Prakati Dr. Monia Prakati <thdr. monia="" prakati<="" th=""> Dr. Monia Prakati</thdr.>	Contract of Contract of Contract	INTERVENTIONAL RADIOLOGY	Dr. Sarang Deshpondo	PHYSIOTHERAPY	Enclosed and the second
Unit Robit Dr. Rosti Dr. Amite Dr. Amite Dr. Amite Dr. Magnobis Dr. Amite Amite Dr. Magnobis Dr. Amite Dr. Magnobis Dr. Amite Dr. Magnobis Dir. Magnobis <thdir. magnobis<="" th=""> <</thdir.>	and the second second		Dr. Mrinal Prakash	Station in the line of the state of the stat	and the second s
Dr. Yoppeder Elsarra RECONTLOCY Dr. Saids Funda REVISION Dr. Saids Funda Dr. Saids Funda Dr. Saids Funda REVEAT REVEAT Dr. Saidser Fund Dr. Saidser Funda Dr. Saidser Funda Dr. Saidser Funda REVEAT Dr. Saidser Funda Dr. Saidse	Rept States	Dr. Ravi Manek	Dr. Aditya Gunjotikar	Bastacholas and a second second	Epineterio de la companya de la comp
Dr. Mohan Patt Dr. Secial Statuture Dir. Statuture Statuture Dir. Statuture Statuture Dir. Statutur	A COLORADO A	NEONATOLOGY	Dr. Satish Puravik	Prostal and a ready to a ready	Carl Handling .
Dr. Puriserii Shah Dr. Dergus Trait MICOLA UNICCOUT Dr. Samara B 06/11317W 06/11317W Dr. Amana D Dr. Mana D	Application and a second secon	Dr. Sechin Sekharker			Residence of the second s
Dr. Jouch Standard Dr. Jouch Standard Dr. Jouch Standard Dr. Journal Sta	HER AND AN				Dr. Stavara Contractives
DEVILUTION CONTRACTOR DE LA Malancia Finanza Englisio Contra de La Malancia Finanza Englis Contra de La Malancia Finanza Englis Contra de La Malancia Revisión Englis Contra de La Malan	UTAMAS AND A CONTRACT OF			A CONTRACTOR OF A CONTRACTOR O	
Dr. Yapasar Teaman Dr. Gastan Katot NEUROLOOV Dr. Yan Yaman Dr. Change Sharing	and the second se		SURGICAL ONCOLOGY	Card and a state of the state o	
Dr. Galuari Kinovi Dr. Vivek Soni Dr. Dipesh Pimpale Dr. Saveys Pandrovala Dr. datwei Kulkani Dr. Vivek Soni Dr. Astwei Kulkani	And the second s				
Dr. Vivek Soni Dr. Hitosh Singhavi Dr. Astwine Aukanti	And a second sec				
DE RIMATOLOGY Dr. Scidenarius romanani Dr. Harish Powar	and the second s	Dr. Siddharth Kharkar		Dr. Astwini Kukami	and the second division of the second divisio
	Dr. Vishalakshi Viswanath		Dr. Navin Bhambhani		

Source: Company, JM Financial



Source: Company, JM Financial

APPENDIX I

JM Financial Institutional Securities Limited

Corporate Identity Number: U67100MH2017PLC296081

Member of BSE Ltd. and National Stock Exchange of India Ltd.

SEBI Registration Nos.: Stock Broker - INZ000163434, Research Analyst - INH000000610

Registered Office: 7th Floor, Cnergy, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India.

Board: +91 22 6630 3030 | Fax: +91 22 6630 3488 | Email: jmfinancial.research@jmfl.com | www.jmfl.com

Compliance Officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1073 | Email: sahil.salastekar@jmfl.com

Grievance officer: Mr. Sahil Salastekar | Tel: +91 22 6224 1073 | Email: instcompliance@jmfl.com

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Definition of ratings				
Rating	Meaning			
Buy	Total expected returns of more than 10% for stocks with market capitalisation in excess of INR 200 billion and REITs* and more than 15% for all other stocks, over the next twelve months. Total expected return includes dividend yields.			
Hold	Price expected to move in the range of 10% downside to 10% upside from the current market price for stocks with market capitalisation in excess of INR 200 billion and REITs* and in the range of 10% downside to 15% upside from the current market price for all other stocks, over the next twelve months.			
Sell	Price expected to move downwards by more than 10% from the current market price over the next twelve months.			

* REITs refers to Real Estate Investment Trusts.

Research Analyst(s) Certification

The Research Analyst(s), with respect to each issuer and its securities covered by them in this research report, certify that:

All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and

No part of his or her or their compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in this research report.

Important Disclosures

This research report has been prepared by JM Financial Institutional Securities Limited (JM Financial Institutional Securities) to provide information about the company(ies) and sector(s), if any, covered in the report and may be distributed by it and/or its associates solely for the purpose of information of the select recipient of this report. This report and/or any part thereof, may not be duplicated in any form and/or reproduced or redistributed without the prior written consent of JM Financial Institutional Securities. This report has been prepared independent of the companies covered herein.

JM Financial Institutional Securities is registered with the Securities and Exchange Board of India (SEBI) as a Research Analyst and a Stock Broker having trading memberships of the BSE Ltd. (BSE) and National Stock Exchange of India Ltd. (NSE). No material disciplinary action has been taken by SEBI against JM Financial Institutional Securities in the past two financial years which may impact the investment decision making of the investor. Registration granted by SEBI and certification from the National Institute of Securities Market (NISM) in no way guarantee performance of JM Financial Institutional Securities or provide any assurance of returns to investors.

JM Financial Institutional Securities renders stock broking services primarily to institutional investors and provides the research services to its institutional clients/investors. JM Financial Institutional Securities and its associates are part of a multi-service, integrated investment banking, investment management, brokerage and financing group. JM Financial Institutional Securities and/or its associates might have provided or may provide services in respect of managing offerings of securities, corporate finance, investment banking, mergers & acquisitions, broking, financing or any other advisory services to the company(ies) covered herein. JM Financial Institutional Securities and/or its associates might have received during the past twelve months or may receive compensation from the company(ies) mentioned in this report for rendering any of the above services.

JM Financial Institutional Securities and/or its associates, their directors and employees may; (a) from time to time, have a long or short position in, and buy or sell the securities of the company(ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) covered under this report or (c) act as an advisor or lender/borrower to, or may have any financial interest in, such company(ies) or (d) considering the nature of business/activities that JM Financial Institutional Securities is engaged in, it may have potential conflict of interest at the time of publication of this report on the subject company(ies).

Neither JM Financial Institutional Securities nor its associates or the Research Analyst(s) named in this report or his/her relatives individually own one per cent or more securities of the company(ies) covered under this report, at the relevant date as specified in the SEBI (Research Analysts) Regulations, 2014.

The Research Analyst(s) principally responsible for the preparation of this research report and their immediate relatives are prohibited from buying or selling debt or equity securities, including but not limited to any option, right, warrant, future, long or short position issued by company(ies) covered under this report. The Research Analyst(s) principally responsible for the preparation of this research report or their immediate relatives (as defined under SEBI (Research Analysts) Regulations, 2014); (a) do not have any financial interest in the company(ies) covered under this report or (b) did not receive any compensation from the company(ies) covered under this report, or from any third party, in connection with this report or (c) do not have any other material conflict of interest at the time of publication of this report. Research Analyst(s) are not serving as an officer, director or employee of the company(ies) covered under this report.

Krishna Institute of Medical Sciences

While reasonable care has been taken in the preparation of this report, it does not purport to be a complete description of the securities, markets or developments referred to herein, and JM Financial Institutional Securities does not warrant its accuracy or completeness. JM Financial Institutional Securities may not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. This report is provided for information only and is not an investment advice and must not alone be taken as the basis for an investment decision.

This research report is based on the fundamental research/analysis conducted by the Research Analyst(s) named herein. Accordingly, this report has been prepared by studying/focusing on the fundamentals of the company(ies) covered in this report and other macro-economic factors. JM Financial Institutional Securities may have also issued or may issue, research reports and/or recommendations based on the technical/quantitative analysis of the company(ies) covered in this report by studying and using charts of the stock's price movement, trading volume and/or other volatility parameters. As a result, the views/recommendations expressed in such technical research reports could be inconsistent or even contrary to the views contained in this report.

The investment discussed or views expressed or recommendations/opinions given herein may not be suitable for all investors. The user assumes the entire risk of any use made of this information. The information contained herein may be changed without notice and JM Financial Institutional Securities reserves the right to make modifications and alterations to this statement as they may deem fit from time to time.

This report is neither an offer nor solicitation of an offer to buy and/or sell any securities mentioned herein and/or not an official confirmation of any transaction.

This report is not directed or intended for distribution to, or use by any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject JM Financial Institutional Securities and/or its affiliated company(ies) to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to a certain category of investors. Persons in whose possession this report may come, are required to inform themselves of and to observe such restrictions.

Additional disclosure only for U.S. persons: JM Financial Institutional Securities has entered into an agreement with JM Financial Securities, Inc. ("JM Financial Securities"), a U.S. registered broker-dealer and member of the Financial Industry Regulatory Authority ("FINRA") in order to conduct certain business in the United States in reliance on the exemption from U.S. broker-dealer registration provided by Rule 15a-6, promulgated under the U.S. Securities Exchange Act of 1934 (the "Exchange Act"), as amended, and as interpreted by the staff of the U.S. Securities and Exchange Commission ("SEC") (together "Rule 15a-6").

This research report is distributed in the United States by JM Financial Securities in compliance with Rule 15a-6, and as a "third party research report" for purposes of FINRA Rule 2241. In compliance with Rule 15a-6(a)(3) this research report is distributed only to "major U.S. institutional investors" as defined in Rule 15a-6 and is not intended for use by any person or entity that is not a major U.S. institutional investor. If you have received a copy of this research report and are not a major U.S. institutional investor, you are instructed not to read, rely on, or reproduce the contents hereof, and to destroy this research or return it to JM Financial Institutional Securities or to JM Financial Securities.

This research report is a product of JM Financial Institutional Securities, which is the employer of the research analyst(s) solely responsible for its content. The research analyst(s) preparing this research report is/are resident outside the United States and are not associated persons or employees of any U.S. registered broker-dealer. Therefore, the analyst(s) are not subject to supervision by a U.S. broker-dealer, or otherwise required to satisfy the regulatory licensing requirements of FINRA and may not be subject to the Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

Any U.S. person who is recipient of this report that wishes further information regarding, or to effect any transaction in, any of the securities discussed in this report, must contact, and deal directly through a U.S. registered representative affiliated with a broker-dealer registered with the SEC and a member of FINRA. In the U.S., <u>JM Financial Institutional Securities has an affiliate</u>, JM Financial Securities, Inc. located at 1325 Avenue of the Americas, 28th Floor, Office No. 2821, <u>New York, New York 10019</u>. Telephone +1 (332) 900 4958 which is registered with the SEC and is a member of FINRA and SIPC.

Additional disclosure only for U.K. persons: Neither JM Financial Institutional Securities nor any of its affiliates is authorised in the United Kingdom (U.K.) by the Financial Conduct Authority. As a result, this report is for distribution only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Financial Promotion Order"), (ii) are persons falling within Article 49(2)(a) to (d) ("high net worth companies, unincorporated associations etc.") of the Financial Promotion Order, (iii) are outside the United Kingdom, or (iv) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000) in connection with the matters to which this report relates may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as "relevant persons"). This report is directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this report relates is available only to relevant persons and will be engaged in only with relevant persons.

Additional disclosure only for Canadian persons: This report is not, and under no circumstances is to be construed as, an advertisement or a public offering of the securities described herein in Canada or any province or territory thereof. Under no circumstances is this report to be construed as an offer to sell securities or as a solicitation of an offer to buy securities in any jurisdiction of Canada. Any offer or sale of the securities described herein in Canada will be made only under an exemption from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or, alternatively, pursuant to an exemption from the registration requirement in the relevant province or territory of Canada in which such offer or sale is made. This report is not, and under no circumstances is it to be construed as, a prospectus or an offering memorandum. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein or the merits of the securities described herein and any representation to the contrary is an offence. If you are located in Canada, this report has been made available to you based on your representation that you are an "accredited investor" as such term is defined in National Instrument 45-106 Prospectus Exemptions and a "permitted client" as such term is defined in National Instrument 45-106 Prospectus Exemptions. Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada nor should it be construed as being tailored to the needs of the recipient. Canadian recipients are advised that JM Financial Securities, Inc., JM Financial Institutional Securities Limited, their affiliates and authorized agents are not responsible for, nor do they accept, any liability whatsoever for any direct or consequential loss arising from any use of this research report or